State of Wisconsin Investment Board Invests $328,000 in Dynavax Technologies Corporation (DVAX) Stock

State of Wisconsin Investment Board purchased a new position in Dynavax Technologies Corporation (NASDAQ:DVAX) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 34,000 shares of the biopharmaceutical company’s stock, valued at approximately $328,000. State of Wisconsin Investment Board owned about 0.07% of Dynavax Technologies Corporation as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also made changes to their positions in DVAX. Teachers Advisors LLC increased its position in Dynavax Technologies Corporation by 9.1% in the fourth quarter. Teachers Advisors LLC now owns 67,640 shares of the biopharmaceutical company’s stock worth $267,000 after purchasing an additional 5,618 shares during the last quarter. Nationwide Fund Advisors increased its position in Dynavax Technologies Corporation by 11.2% in the first quarter. Nationwide Fund Advisors now owns 27,667 shares of the biopharmaceutical company’s stock worth $165,000 after purchasing an additional 2,786 shares during the last quarter. Russell Investments Group Ltd. increased its position in Dynavax Technologies Corporation by 61.7% in the first quarter. Russell Investments Group Ltd. now owns 125,059 shares of the biopharmaceutical company’s stock worth $744,000 after purchasing an additional 47,735 shares during the last quarter. Wells Fargo & Company MN increased its position in Dynavax Technologies Corporation by 30.0% in the first quarter. Wells Fargo & Company MN now owns 41,743 shares of the biopharmaceutical company’s stock worth $248,000 after purchasing an additional 9,634 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale bought a new stake in Dynavax Technologies Corporation in the first quarter worth $121,000. Institutional investors own 60.23% of the company’s stock.

Several equities research analysts recently weighed in on DVAX shares. William Blair restated an “outperform” rating and issued a $30.00 price target on shares of Dynavax Technologies Corporation in a research report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. J P Morgan Chase & Co upgraded shares of Dynavax Technologies Corporation from a “neutral” rating to an “overweight” rating and boosted their price target for the stock from $6.00 to $27.00 in a research report on Monday, July 31st. BidaskClub cut shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Finally, Cowen and Company restated an “outperform” rating and issued a $45.00 price target on shares of Dynavax Technologies Corporation in a research report on Thursday, July 27th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $24.80.

TRADEMARK VIOLATION WARNING: “State of Wisconsin Investment Board Invests $328,000 in Dynavax Technologies Corporation (DVAX) Stock” was published by Transcript Daily and is owned by of Transcript Daily. If you are accessing this piece on another site, it was illegally copied and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this piece can be read at https://transcriptdaily.com/2017/09/15/state-of-wisconsin-investment-board-invests-328000-in-dynavax-technologies-corporation-dvax-stock.html.

Dynavax Technologies Corporation (DVAX) opened at 20.60 on Friday. The company’s market cap is $1.13 billion. The firm’s 50-day moving average is $17.04 and its 200-day moving average is $9.40. Dynavax Technologies Corporation has a 52-week low of $3.20 and a 52-week high of $21.85.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative return on equity of 92.09% and a negative net margin of 1,323.99%. The business had revenue of $0.11 million during the quarter, compared to the consensus estimate of $0.15 million. During the same period last year, the company earned ($0.75) EPS. On average, equities research analysts anticipate that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

Dynavax Technologies Corporation Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Want to see what other hedge funds are holding DVAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Corporation (NASDAQ:DVAX).

Institutional Ownership by Quarter for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply